Lung cancer cell changes and aggressiveness study
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how lung cancer cells change and become more aggressive in people with non-small cell lung cancer (the most common type). It is for patients who have just been diagnosed and are scheduled for surgery without any prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung adenocarcinoma (a type of non-small cell lung cancer)
- You have not yet received any treatment for your cancer (such as chemotherapy, immunotherapy, or radiation therapy)
- You are scheduled to have surgery to remove the tumor as your first treatment
- You have not had any other type of cancer in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung cancer tumor tissue to find genetic “on/off” changes and why treatments may stop working. It may help your care team choose better next tests or treatments based on what the tumor is doing.
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
This study looks at the medical records of people with advanced non-small cell lung cancer to understand what treatments they received and whether those treatments follow official guidelines. It may help doctors learn how to improve care for future patients.
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
This study is looking at how non-small cell lung cancer (NSCLC) changes and progresses over time, from early to advanced stages. By studying people with all stages of the disease, researchers hope to learn more about what affects a person's prognosis and how the cancer evolves. This may help doctors better understand the cancer and develop better treatments.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.